Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC 50 of 7.1. GSK2646264 also inhibits other kinases with pIC 50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK , LRRK2 , GSK3β , JAK2 , VEGFR2 , Aurora B and Aurora A , respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin
In Vitro
GSK2646264 (0.01-10 μM; 1 h) significantly inhibits anti‐IgE (but not C5a)‐induced histamine release from skin mast cells in a concentration‐dependent manner. The IC 50 is 0.7 μM and the IC 90 is 6.8 μM. GSK2646264 cream (0.5, 1, and 3% [wt/wt]; 1 cm 2 ; 4 and 24 h) inhibits anti‐IgE‐induced histamine release from mast cells in ex vivo human skin. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:SYK 7.1 (pIC 50 ) LCK 5.4 (pIC 50 ) LRRK2 5.4 (pIC 50 ) GSK3β 5.3 (pIC 50 ) JAK2 5 (pIC 50 ) VEGFR2 4.5 (pIC 50 ) Aurora B <4.6 (pIC 50 ) Aurora A <4.3 (pIC 50 )
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Solubilità | DMSO : 50 mg/mL (133.52 mM; ultrasonic and warming and heat to 60°C) |
|---|---|
| Peso molecolare | 374.500 g/mol |
| XLogP3 | 4.200 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 374.199 Da |
| Monoisotopic Mass | 374.199 Da |
| Topological Polar Surface Area | 43.400 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 474.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |